Entrust Global Partners’s IGM Biosciences IGMS Stock Holding History

Entrust Global Partners’s Portfolio IGMS Stock Details IGMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-66,172	Closed	-$1.94M	–	15
2021 Q4	$1.94M	Buy	+66,172	New	+$3.29M	0.54%	13

Other funds holding IGMS

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Entrust Global Partners's IGMS Position: Q1 2022 in Review

Entrust Global Partners sold out of IGM Biosciences (IGMS) in Q1 2022, closing a stake of 66,172 shares — an estimated $1.94M sold.

Entrust Global Partners first reported a position in IGMS in Q4 2021 and held it in 1 quarter. The position peaked at $1.94M in Q4 2021. 93 funds tracked by Wall St. Rank hold IGMS as of Q1 2022.

Entrust Global Partners reported no remaining IGM Biosciences position as of Q1 2022 after selling out during the quarter.
Entrust Global Partners sold 66,172 IGM Biosciences shares in Q1 2022, an estimated $1.94M.
Entrust Global Partners first reported a position in IGM Biosciences in Q4 2021 and held it in 1 quarter.
Entrust Global Partners's IGM Biosciences position peaked at $1.94M in Q4 2021.
93 funds tracked by Wall St. Rank held IGM Biosciences as of Q1 2022.

Based on Entrust Global Partners's 13F filing for Q1 2022, filed 12 May 2022.